Breakthrough Glaucoma Treatment Awareness Campaign Offers Relief from Drops at NoDrops.com.

FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Feb. 22, 1999--Gary R. Smith, President, Coronado Industries, Inc. (OTC BB:CDIK) announces today, that in preparation to begin marketing its breakthrough treatment for glaucoma, the Company has created an Information & Registration Web Site for those on the Internet who wish to evaluate the company's treatment. This announcement also invites physicians to consider the company's technology as a treatment for their patients suffering from Glaucoma.

Through the registration information collected online, the Company intends to introduce interested patients of glaucoma to physicians interested in utilizing the Company's breakthrough technology. Family members of glaucoma patients are encouraged to register online as well.

Recently the Company registered through Network Solutions, Inc. (NASDAQ:NSOL) Internic.net for its first choice as a web address and received it! (http://www.NoDrops.com) The domain name NoDrops.com makes a statement to those who suffer from glaucoma. Currently, pharmaceutical manufacturers such as Pharmacia & Upjohn (NYSE:PNU), Lifecore Biomedical, Inc. (NASDAQ:LCBM), Merck & Co. (NYSE:MRK), Allergan, Inc. (NYSE:AGN), produce an eye drop that glaucoma patients take to slow down the disease. The statement our web address is making offers another avenue of hope, freedom from the eye drop treatment!

Coronado Industries, Inc. (OTC BB:CDIK), through its wholly owned subsidiary, Ophthalmic International, Inc., owns the patent rights to a vacuum fixation device and a medical procedure which can be used to treat Open Angle and Pigmentary Glaucoma.

In the United States, glaucoma is the 2nd leading cause of blindness. About 2 million Americans are affected, with the number growing as the population ages. Of those, about 60,000 are legally blind. If detected and treated early, glaucoma need not cause blindness nor severe vision loss. However, at present there is no cure for glaucoma. This group of diseases has a single feature in that it produces progressive damage to the optic nerve due to increased pressure within the eyeball. As the optic nerve deteriorates, blind spots and patterns develop. If left untreated, the result may be total blindness.

The initial studies on the Company's patented device and process indicate that it yields effective results for approximately 75% to 80% of all people with such conditions. Certain ethnic populations, such as Asians, have a higher incidence of the condition. Noting the worldwide incidence of the condition, the Company concludes there is a multimillion-dollar market for the Company's patented process, equipment and rings.

The approval of the patent entitled "Open Angle Glaucoma Treatment Apparatus and Method" should allow the Company to achieve a significant market advantage over any future competitor.

In addition, the Company will be changing the labeling on the equipment from a "vacuum fixation device" to a "glaucoma treatment device". This labeling requires FDA approval. The Company's treatment is a "Non-Invasive Procedure." With this treatment the Company believes that there are no harmful side effects, such as those associated with eye drop treatments.

Any investment in these designated securities should be considered highly speculative. Investment in these securities may not be a suitable investment for you. An investment in these securities could result in a total loss of your investment. The company recommends that any prospective investor consult with his investment advisor or broker prior to investing in the company's securities. Additional information on the company can be obtained by making a request of the company or your broker for a current periodic report.